SUMMARY OF THE PAPER
The paper entitled "Assessment of Liver Morbidity in Breast Cancer patients receiving chemotherapy in Suez Canal University Hospitals in Ismailia"(page 3). The authors enrolled 88 female patients who received chemotherapy for breast cancer aiming to assess liver morbidity in breast cancer patients before and 3 months after chemotherapy to assess reactivation of viral hepatitis. They performed basic investigations together with Tri-phasic CT abdomen if there were focal hepatic lesions & then 3 months after completing chemotherapy. The chemotherapeutic regimens of each patient were given according to the standard protocol for the specific tumor type. Viral markers (HBsAg, HBsAb, & Anti-HBcIgG, HCV Ab) were done for all consecutive breast cancer patients who received cytotoxic chemotherapy. They found that Chemotherapy for breast cancer carries high risk for hepatotoxicity and reactivation of viral hepatitis especially HBV.
COMMENT ON THE STUDY
The frequency of chemotherapy induced liver morbidity among breast cancer patients is not exactly known but the number of patients in this study is small to achieve clinical significance. The results support the role of chemotherapy in reactivation of viral hepatitis and drug induced hepatotoxicity without stress on the type of chemotherapy that associated with either hepatotoxicity or viral reactivation.
RECOMMENDATIONS
Multicenter studies are required to determine the exact frequency of liver morbidity after chemotherapy, in breast cancer patients, and proper understanding of the preventive measures that could reduce viral reactivation.
